GTEx Blood 20-29 vs 60-69 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx Blood 20-29 vs 60-69 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx Blood 20-29 vs 60-69 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx Blood 20-29 vs 60-69 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx Blood 20-29 vs 60-69 Up.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 261

Gene

LIF antisense RNA 2

Gene

killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene)

Gene

NR4A1 antisense RNA

Gene

H2B clustered histone 10

Gene

up-regulated in colorectal cancer liver metastasis

Gene

C-C motif chemokine ligand 16

Gene

ribosomal protein S14 pseudogene 1

Gene

small nucleolar RNA, C/D box 14E

Gene

B3GAT1 divergent transcript

  • Gene

    long intergenic non-protein coding RNA 261


  • Gene

    LIF antisense RNA 2


  • Gene

    killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene)


  • Gene

    NR4A1 antisense RNA


  • Gene

    H2B clustered histone 10


  • Gene

    up-regulated in colorectal cancer liver metastasis


  • Gene

    C-C motif chemokine ligand 16


  • Gene

    ribosomal protein S14 pseudogene 1


  • Gene

    small nucleolar RNA, C/D box 14E


  • Gene

    B3GAT1 divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.